Case Reports
doi: 10.1016/j.ygyno.2004.12.001.
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
Affiliations
- PMID: 15721449
- DOI: 10.1016/j.ygyno.2004.12.001
Item in Clipboard
Case Reports
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
Gynecol Oncol.
2005 Mar.
Abstract
Background: Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches.
Case: A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.
Conclusion: Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.
Similar articles
-
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.Gynecol Oncol. 2006 Aug;102(2):140-4. doi: 10.1016/j.ygyno.2006.05.006. Epub 2006 Jun 21. Gynecol Oncol. 2006. PMID: 16790264
-
Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.Gynecol Oncol. 2006 Jul;102(1):5-7. doi: 10.1016/j.ygyno.2006.03.048. Epub 2006 May 12. Gynecol Oncol. 2006. PMID: 16697451
-
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.J Clin Oncol. 2007 Nov 20;25(33):5180-6. doi: 10.1200/JCO.2007.12.0782. J Clin Oncol. 2007. PMID: 18024865 Clinical Trial.
-
Experience with bevacizumab in the management of epithelial ovarian cancer.J Clin Oncol. 2007 Jul 10;25(20):2902-8. doi: 10.1200/JCO.2007.12.1509. J Clin Oncol. 2007. PMID: 17617521 Review.
-
Bevacizumab in the treatment of ovarian cancer.Adv Ther. 2012 Sep;29(9):723-35. doi: 10.1007/s12325-012-0041-9. Epub 2012 Aug 21. Adv Ther. 2012. PMID: 22941523 Review.
Cited by
-
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.Breast Cancer (Dove Med Press). 2010 Jun 21;2:37-44. doi: 10.2147/bctt.s6511. Breast Cancer (Dove Med Press). 2010. PMID: 24367165 Free PMC article. Review.
-
Novel short peptides isolated from phage display library inhibit vascular endothelial growth factor activity.Mol Biotechnol. 2007 Jan;35(1):51-63. doi: 10.1385/mb:35:1:51. Mol Biotechnol. 2007. PMID: 17401149
-
B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.Gynecol Oncol. 2014 Jul;134(1):181-189. doi: 10.1016/j.ygyno.2014.03.553. Epub 2014 Mar 20. Gynecol Oncol. 2014. PMID: 24657487 Free PMC article. Review.
-
Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.Res Sq [Preprint]. 2023 May 8:rs.3.rs-2887299. doi: 10.21203/rs.3.rs-2887299/v1. Res Sq. 2023. Update in: Cancer Immunol Immunother. 2023 Nov;72(11):3773-3786. doi: 10.1007/s00262-023-03529-w. PMID: 37214945 Free PMC article. Updated. Preprint.
-
Emerging treatment options for management of malignant ascites in patients with ovarian cancer.Int J Womens Health. 2012;4:395-404. doi: 10.2147/IJWH.S29467. Epub 2012 Aug 3. Int J Womens Health. 2012. PMID: 22927770 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
